Selank vs. Semax: Research Peptide Comparison

For laboratory research use only; not for human consumption.

Two heptapeptides from one research tradition

Selank and Semax are grouped together constantly in peptide research discussions, largely because both originated in Russian pharmacological research and both are short synthetic peptides studied for central nervous system-related endpoints. Beyond that shared origin, the two molecules are structurally distinct, derive from different parent proteins, and are typically studied for different research questions. This comparison lays out where the overlap is and where it is not. Individual background is in the Selank research overview and the Semax research overview.

Different parent molecules, different starting points

Selank is a synthetic heptapeptide built as an extended analog of tuftsin, an immunomodulatory tetrapeptide naturally cleaved from the Fc domain of immunoglobulin G. The tuftsin backbone was extended with a Pro-Gly-Pro tripeptide, producing a molecule studied largely for its stability advantage over native tuftsin, which is degraded very quickly in biological systems.

Semax derives from adrenocorticotropic hormone (ACTH). Its core is the N-terminal ACTH sequence Met-Glu-His-Phe, which lacks the hormonal activity of full-length ACTH but was identified as retaining central nervous system effects in early Russian research, again extended with Pro-Gly-Pro for stability. Some descriptions call it an ACTH(4-10) analog; the V8 Peptides product page uses that wording while the listed sequence is the seven-residue form, so the sequence on the certificate is the thing to rely on.

The shared Pro-Gly-Pro tail is the one real structural echo between the two, and it is a stabilizing C-terminal extension rather than a shared pharmacophore. Despite both being called "nootropic peptides" informally, they are not structural analogs of each other: they are contemporaries from one research lineage, not variations on one scaffold.

Where preclinical research attention has focused

Published preclinical work on Selank concentrates on anxiolytic-adjacent models: animal studies of stress-response behavior, GABAergic interactions, and modulation of immune-signaling markers alongside behavioral endpoints. It also touches on interactions with enkephalin-degrading enzymes, a proposed and still actively studied mechanistic pathway.

Semax research trends in a different direction. Cognitive and neurotrophic endpoints dominate: studies of brain-derived neurotrophic factor (BDNF) expression, attention and learning-task performance in rodent models, and neuroprotective outcomes in models of induced ischemia. Neither research direction implies a confirmed human outcome. Both are preclinical, animal-model and in-vitro literatures, and the proposed pathways are still being characterized rather than settled.

Mechanism: distinct targets, some pathway overlap

The proposed mechanism for Selank centers on modulation of enzymatic degradation of endogenous enkephalins, plus downstream effects on GABA-A receptor sensitivity measured in some animal models. Its immunomodulatory heritage via tuftsin shows up in research examining cytokine expression alongside behavioral markers.

The proposed mechanism for Semax is built around upregulation of neurotrophic factors, particularly BDNF and NGF (nerve growth factor), along with effects on monoamine activity; dopamine and serotonin turnover have both been examined. Some pathway components overlap, since both peptides have been studied in models touching the melanocortin and opioid-peptide systems to varying degrees, but the dominant proposed mechanisms differ.

Experimental design: choosing between them

The choice follows the research question, not a ranking. A lab modelling stress-response behavior or immune-signaling readouts will find more precedent for Selank; a lab examining neurotrophic gene expression or learning-task endpoints will find more for Semax. Some labs run them in parallel or sequentially because their proposed mechanisms look complementary rather than redundant. Such designs should still regard them as two separately characterized compounds with their own purity, identity and documentation requirements, never as interchangeable options. Where a protocol uses both, keep separate lot numbers and separate controls for each.

Both peptides are frequently described in intranasal animal studies, owing to reported blood-brain-barrier penetration characteristics for short peptides delivered that way. That is a feature of the published models and not a claim about any other use. Related reading: what is Selank, what is Semax and the N-acetyl Semax amidate vs. Semax comparison.

Reading the literature critically

Much of the Selank and Semax literature is regional, published in a small number of journals and research groups, and written under different experimental conventions from most Western pharmacology work. That does not make it wrong, but it does mean a careful reader should look for independent replication, check which species and which model were used, and note whether the peptide was characterized analytically in the paper. Early papers often give little detail on peptide purity, so observed effects can be difficult to attribute to the named sequence rather than to impurities or salts. Mechanistic claims such as enkephalinase inhibition or BDNF upregulation are best read as hypotheses supported by specific assays, not as established facts about the whole organism.

Comparisons between the two across studies are also hard, because the models, endpoints and administration routes rarely match. When a protocol needs a direct comparison, running both within the same experiment, with the same readouts and separately verified material, is more informative than reading across papers.

Analytical differences that help verify each compound

Both are small, so a single mass spectrum distinguishes them cleanly: Selank near 752 Da and Semax near 814 Da. They also separate on reversed-phase HPLC. Selank is strongly basic, carrying lysine and arginine, and elutes early on a typical gradient; Semax is more hydrophobic (phenylalanine and methionine) and elutes later. Semax's methionine adds one particular quality concern, oxidation to the sulfoxide, which shows as a +16 Da species and an early-eluting shoulder. Selank has no such residue, so its typical impurities are deletion sequences from the proline-rich synthesis. Compound-specific testing guides are in Selank purity testing and Semax purity testing.

Sourcing considerations

Whichever compound a protocol calls for, the checklist is the same: HPLC-verified purity, mass-spectrometry-confirmed identity and a batch-specific certificate. See HPLC purity analysis, how to read a CoA and the supplier checklist. Compound-specific buyer's guides are at where to buy Selank and where to buy Semax.

V8 Peptides lists both as lyophilized powder with a purity specification of ≥98% by HPLC. See the Selank research vial and Semax research vial product pages for current specifications and the certificate of analysis page for batch documents. Concentration math for either is simple: 10 mg of Selank in 2 mL is 5 mg/mL, and the calculator handles other volumes. Store lyophilized material at 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light.

Selank vs. Semax FAQ

Are Selank and Semax structural analogs of each other?

No. Selank is derived from tuftsin and Semax from an ACTH fragment. They share only a Pro-Gly-Pro stabilizing tail.

Which one is studied for stress-response models?

Selank, whose preclinical literature centers on anxiolytic-adjacent and immune-signaling endpoints.

Which one is studied for neurotrophic endpoints?

Semax, whose literature centers on BDNF and NGF expression, learning tasks and ischemia models in animals.

Does the research show outcomes in humans?

No confirmed human outcome is implied. The bodies of work described here are preclinical, using animal models and in-vitro systems.

How can I tell them apart analytically?

By mass: about 752 Da for Selank and about 814 Da for Semax. They also elute at different points on a reversed-phase gradient.

What is the typical quality concern for Semax?

Methionine oxidation, seen as a +16 Da species and an early shoulder on the main HPLC peak.

What vial sizes does V8 Peptides list?

Selank in a 10 mg vial and Semax in a 15 mg vial, both lyophilized with a listed purity of at least 98% by HPLC.

Can they be used together in a study?

Some labs run them in parallel because the proposed mechanisms look complementary. Each needs its own documentation and separate controls.

For laboratory research use only; not for human consumption. This article is research education, not usage guidance.

References

1. Selank research overview
2. Semax research overview
3. Understanding HPLC purity
4. How to read a CoA
5. Certificate of analysis page
6. Selank product page
7. Semax product page

Research Use Only. Supplied strictly for laboratory research and development; not for human or veterinary use, consumption, or any clinical or diagnostic purpose.